Vimarsana
Biggest News Aggregation in the World

Bing Yan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bing Yan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bing Yan Today - Breaking & Trending Today

Insider Sell: Cytek Biosciences Inc's CTO Ming Yan Disposes of 20,000 Shares - Vimarsana News

Insider Sell: Cytek Biosciences Inc's CTO Ming Yan Disposes of 20,000 Shares

Ming Yan, Chief Technology Officer of Cytek Biosciences Inc (NASDAQ:CTKB), sold 20,000 shares of the company on December 19, 2023, according to a recent SEC Filing.

Source: yahoo.com
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor) - Vimarsana News

Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC - Vimarsana News

Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation ROS1 TKI taletrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer with prior exposure to a ROS1 TKI.

AnHeart Therapeutics and Innovent Announce China's NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor) | National Business - Vimarsana News

AnHeart Therapeutics and Innovent Announce China's NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor) | National Business

NEW YORK & SUZHOU, China--(BUSINESS WIRE)--Nov 22, 2023--

AnHeart Therapeutics and Innovent Announce China's NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor) | Region - Vimarsana News

AnHeart Therapeutics and Innovent Announce China's NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor) | Region

NEW YORK & SUZHOU, China--(BUSINESS WIRE)--Nov 22, 2023--